Marshall Wace LLP Increases Stock Position in CymaBay Therapeutics Inc (NASDAQ:CBAY)

Marshall Wace LLP raised its position in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 17.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,589 shares of the biopharmaceutical company’s stock after purchasing an additional 9,231 shares during the period. Marshall Wace LLP owned about 0.09% of CymaBay Therapeutics worth $844,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in CymaBay Therapeutics by 47.4% in the 4th quarter. Rhumbline Advisers now owns 77,946 shares of the biopharmaceutical company’s stock valued at $613,000 after acquiring an additional 25,057 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of CymaBay Therapeutics by 23.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 2,460 shares during the last quarter. BlackRock Inc. increased its holdings in shares of CymaBay Therapeutics by 16.3% in the 4th quarter. BlackRock Inc. now owns 5,161,581 shares of the biopharmaceutical company’s stock worth $40,622,000 after buying an additional 722,753 shares during the last quarter. Eagle Asset Management Inc. increased its holdings in shares of CymaBay Therapeutics by 0.3% in the 4th quarter. Eagle Asset Management Inc. now owns 2,852,973 shares of the biopharmaceutical company’s stock worth $22,452,000 after buying an additional 8,207 shares during the last quarter. Finally, Raymond James & Associates increased its holdings in shares of CymaBay Therapeutics by 7.7% in the 4th quarter. Raymond James & Associates now owns 82,205 shares of the biopharmaceutical company’s stock worth $647,000 after buying an additional 5,899 shares during the last quarter. Institutional investors own 99.53% of the company’s stock.

Shares of NASDAQ CBAY traded down $0.21 during trading hours on Friday, hitting $6.22. 473,618 shares of the stock were exchanged, compared to its average volume of 893,247. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.66 and a current ratio of 18.66. CymaBay Therapeutics Inc has a 12 month low of $4.82 and a 12 month high of $14.00. The firm has a market capitalization of $441.70 million, a P/E ratio of -4.94 and a beta of 1.26. The firm’s fifty day simple moving average is $7.86.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). Research analysts predict that CymaBay Therapeutics Inc will post -1.49 EPS for the current year.

Several brokerages recently commented on CBAY. Oppenheimer set a $12.00 price target on shares of CymaBay Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 11th. HC Wainwright reissued a “neutral” rating on shares of Aerpio Pharmaceuticals in a research report on Wednesday, June 12th. Raymond James set a $86.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, April 23rd. B. Riley set a $71.00 price objective on shares of Brunswick and gave the company a “buy” rating in a research report on Monday, June 17th. Finally, Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $14.00.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Read More: What is the Federal Reserve?

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.